The article discusses a recent ruling by the 5th U.S. Circuit Court of Appeals regarding the FDA’s approval of mifepristone, a medication used in medication abortions. The court upheld a lower court ruling that significantly restricts access to mifepristone, though it didn’t fully reinstate the pre-2000 regulations.
Specifically, the appeals court upheld the lower court’s decision to prohibit mailing the drug and require it to be prescribed and dispensed in person by a physician, effectively reversing FDA actions that had made the drug more accessible. The ruling argues that the FDA didn’t adequately consider the safety risks associated with the drug, particularly for minors, when it loosened regulations.
The article frames this ruling as a victory for anti-abortion activists and a setback for abortion rights advocates. It emphasizes the potential consequences for women’s access to abortion, particularly in states where abortion is legal but access is already limited. It points out that restricting mifepristone availability will likely increase the burden on clinics and hospitals providing surgical abortions, and could push women to seek unsafe alternatives. The ruling is currently stayed by the Supreme Court while the case is considered further.
find the original article here: https://www.yahoo.com/news/dangerous-anti-abortion-victory-buried-185107546.html